Does body mass index, smoking, lipoprotein levels, surgically induced menopause, hormone replacement therapy, years since menopause, or age affect hemostasis in postmenopausal women?

Gender Medicine

Volumn 2, Issue 2, 2005, Pages 88-95

  Pripp, Ulla ^a   Eriksson Berg, Margita ^a   Orth Gomér, Kristina ^b   Schenck Gustafsson, Karin ^a   Landgren, Britt Marie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Body mass index; Hemostasis; Hormone replacement therapy; Lipoproteins; Postmenopausal; Women

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FIBRINOGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; SMOKING; SWEDEN;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HUMANS; HYSTERECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; REGRESSION ANALYSIS; SMOKING;

EID: 20944438310     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(05)80015-4     Document Type: Article

References (39)

1. Rich-Edwards J.W. Manson J.E. Hennekens C.H. Buring J.E. The primary prevention of coronary heart disease in women N Engl J Med 332 1995 1758-1766
2. Kannel W.B. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study Am Heart J 114 1987 413-419
3. Burger H.G. The endocrinology of the menopause Maturitas 23 1996 129-136
4. Stampfer M.J. Colditz G.A. Willett W.C. et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study N Engl J Med 325 1991 756-762
5. Nabulsi A.A. Folsom A.R. White A. Atherosclerosis Risk in Communities Study Investigators et al. Atherosclerosis Risk in Communities Study Investigators Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women N Engl J Med 328 1993 1069-1075
6. Rossouw J.E. Anderson G.L. Prentice R.L. et al. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial JAMA 288 2002 321-333
7. Stevenson J.C. Crook D. Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women Atherosclerosis 98 1993 83-90
8. Darling G.M. Johns J.A. McCloud P.I. Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women N Engl J Med 337 1997 595-601
9. Lobo R.A. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women J Clin Endocrinol Metab 73 1991 925-930
10. Bush T.L. Barrett-Connor E. Cowan L.D. et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lip id Research Clinics Program Follow-up Study Circulation 75 1987 1102-1109
11. Winkler U.H. Menopause, hormone replacement therapy and cardiovascular disease: A review of haemostaseological findings Fibrinolysis 6 Suppl 3 1992 5-10
12. Meade T.W. Haines A.P. Imeson J.D. et al. Menopausal status and haemostatic variables Lancet 1 1983 22-24
13. Lowe G.D. Rumley A. Woodward M. et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age,sex and hormone use Br J Haematol 97 1997 775-784
14. Scarabin P.Y. Vissac A.M. Kirzin J.M. et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII Arterioscler Thromb Vasc Biol 16 1996 1170-1176
15. Orth-Gomer K. Mittleman M.A. Schenck-Gustaffson K. et al. Lipoprotein(a) as a determinant of coronary heart disease in young women Circulation 95 1997 329-334
16. Al-Khalili F. Svane B. Janszky I. et al. Significant predictors of poor prognosis in women
17. Jungner I. Walldius G. Holme I. et al. Apolipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females Int I Clin Lab Res 21 1992 247-255
18. Glueck C.J. Taylor H.L. Jacobs D. Lipid Research Clinics Program Prevalence Study et al. Plasma high-density lipoprotein cholesterol: Association with measurements of body mass Circulation 62 1980 IV-62-IV-69
19. Vermylen C. de Vreker R.A. Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test) Clin Chim Acta 8 1963 418-424
20. Amiral J. Adalbert B. Adam M. Application of enzyme immunoassays to coagulation testing Clin Chem 30 1984 1512-1516
21. Wildgoose P. Nemerson Y. Hansen L.L. et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients Blood 80 1992 25-28
22. Morrissey J.H. Macik B.G. Neuenschwander P.F. Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation Blood 81 1993 734-744
23. Wiman B. Chmielewska J. Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor J Biol Chem 259 1984 3644-3647
24. Meilahn E.N. Kuller L.H. Matthews K.A. Kiss J.E. Hemostatic factors according to menopausal status and use of hormone replacement therapy Ann Epidemiol 2 1992 445-455
25. Wamala S.P. Murray M.A. Horsten M. et al. Socioeconomic status and determinants of hemostatic function in healthy women Arterioscler Thromb Vasc Biol 19 1999 485-492
26. Balleisen L. Bailey J. Epping P.H. et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender,body-weight, smoking, alcohol, pill-using, and menopause Thromb Haemost 54 1985 475-479
27. Scarabin P.Y. Alhenc-Gelas M. Plu-Bureau G. et al. Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomizedcontrolled trial Arterioscler Thromb Vasc Biol 17 1997 3071-3078
28. Kroon U.B. Silfverstolpe G. Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables Thromb Haemost 71 1994 420-423
29. Gottsater A. Rendell M. Hulthen U.L. et al. Hormone replacement therapy in healthy postmenopausal women: A randomized, placebo controlled study of effects on coagulation and fibrinolytic factors J Intern Med 249 2001 237-246
30. Vehkavaara S. Silveira A. Hakala-Ala-Pietila T. et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids andlipoproteins in postmenopausal women Thromb Haemost 85 2001 619-625
31. Grodstein F. Stampfer M.J. Colditz G.A. et al. Postmenopausal hormone replacement therapy and mortality N Engl J Med 336 1997 1769-1775
32. Psaty B.M. Heckbert S.R. Atkins D. et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in post menopausal women Arch Intern Med 154 1994 1333-1339
33. Daly E. Vessey M.P. Hawkins M.M. et al. Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977-980
34. Caine Y.G. Bauer K.A. Barzegar S. et al. Coagulation activation following estrogen administration to postmenopausal women Thromb Haemost 68 1991 392-395
35. Folsom A.R. Wu K.K. Davis C.E. et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors Atherosclerosis 91 1991 191-205
36. Mennen L.I. Schouten E.G. Grobbee D.E. Kluft C. Coagulation factor VII, dietary fat and blood lipids: A review Thromb Haemost 76 1996 492-499
37. Al-Khalili F. Landgren B.M. Eksborg S. et al. Does sublingual 17-beta-oestradiol have any effects on exercise capacity and myocardial ischaemia in post-menopausal women with stable coronaryartery disease? Eur Heart J. 19 1998 1019-1026
38. Sorensen M.B. Collins P. Ong P.J. et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothe lial function assessed by cardiovascularmagnetic resonance Circulation 106 2002 1646-1651
39. Koh K.K. Mincemoyer R. Bui M.N. et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women N. Engl. J. Med. 1997 336 683-690